font size
Sign inprintPrint

DEALMAKING:

Astellas Turns Up the Heat

Suitor sues OSI, adding pressure to its hostile bid.


Astellas Pharma's $3.5 billion hostile takeover bid for OSI Pharmaceuticals grew a little more bitter March 2, as Astellas sued OSI to keep it from using a poison pill to fend off its advances. The suit seeks an injunction against any action that would block Astellas’ tender offer for Melville, New York-based OSI's shares “in a manner inconsistent with the directors’ fiduciary duties.” The prize Astellas is after: OSI's treatment for advanced non-small cell lung cancer and advanced pancreatic cancer, Tarceva, which could be just the edge the Japanese pharma needs to compensate for Japan's increasing shift toward cheaper generics. Read More
Other recent stories